EValuation of Erlotinib as a Neoadjuvant Therapy in Stage III Non-small Cell Lung Cancer Patients With EGFR Mutations (EVENT Trial)
Phase of Trial: Phase II
Latest Information Update: 04 Feb 2019
Price : $35 *
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms EVENT
- 31 Aug 2018 Biomarkers information updated
- 27 Mar 2018 Status changed from recruiting to discontinued.
- 23 Jan 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2017.